Osteoporosis: the current status of mesenchymal stem cell-based therapy.

Background

Osteoporosis, a bone disease involving the appearance of porous bone, is characterized by low bone mass and microarchitectural deterioration of bone tissues, leading to reduced bone strength and a consequent increase in fracture risk [ 1 , 2 ]. Osteoporosis is increasingly recognized as a major public health concern that affects more than 200 million people worldwide and causes more than 8.9 million fractures, and mainly hip fractures, per year [ 3 ]. The incidence of osteoporosis has dramatically risen because the life expectancy of the population has been increasing in every geographic region [ 4 ]. The consequences of osteoporosis are significant, as is the financial burden, estimated at approximately US $17 billion for more than 2 million fractures in the US [ 5 ]. The prevention of this disease and its associated fractures is considered essential to health maintenance, quality of life, and independence in the elderly population.

According to the World Health Organization (WHO) criteria, osteoporosis is defined as having a bone mineral density (BMD) value that is 2.5 standard deviations or more (T-score ≤ -2.5) below the average value for young healthy women, as measured by dual-energy x-ray absorptiometry (DXA), which is the most validated technique (i.e., the gold standard) [ 1 , 2 ]. A low BMD not only is a major risk factor for fractures but also is an independent risk factor for death [ 6 ]. BMD testing of the hip and spine is required for a densitometric diagnosis of osteoporosis. Measurements of bone strength other than bone density at these sites may predict fracture risk but cannot be used to diagnose osteoporosis [ 7 ]. BMD remains the best tool to assess fracture risk, but it cannot predict the fracture risk in certain cases, particularly in type 2 diabetes patients, who usually have a higher BMD and an increased fracture risk [ 8 ]. The majority of osteoporotic fractures occur in individuals with a BMD level within the osteopenic range (-2.5 < T-score < -1) or even with normal BMD levels [ 9 ]. The Fracture Risk Assessment (FRAX) tool integrates BMD and clinical risk factors such as age, gender, the history of fracture, the parental history of hip fracture, current smoking, excessive alcohol intake, rheumatoid arthritis, glucocorticoid use, and other causes of secondary osteoporosis. FRAX has been shown to be a more applicable prediction tool to estimate the risk and probability of fracture in an individual over the next 10 years. FRAX can also provide general clinical guidance for treatment decisions [ 10 ].

Over the past few decades, there have been great advances in understanding of the physiologic process of bone remodeling, together with associated pathologic conditions. The underlying pathogenesis of osteoporosis involves an imbalance of bone homeostasis that results from many causes, such as hormone deficiency, genetic disorders, use of certain medications, and medical conditions. Osteoporosis is characterized by low bone mass and density, which lead to an increased fracture risk. The aims of treatment for osteoporosis are to reduce bone loss and maintain bone density, especially in patients who have fractures or a high risk of fractures. Many therapeutic drugs for treating osteoporosis are available in the market, most of which have relied on bone resorption inhibition, such as bisphosphonate, and several drugs are being developed for treatment in the future. However, controversies have confounded the treatment of osteoporosis. Thus, new treatments based on the promotion of bone regeneration or alternative cell-based therapy for osteoporosis patients are expected to be investigated. Stem cells are expected to have great therapeutic potential, particularly in regenerative medicine. Specifically, stem cells could be a promising cell source for cell-based therapy for osteoporosis. In the present review, the current understanding of mesenchymal stem cells (MSCs) and their roles in osteoporosis, the genetics and transcriptional regulation involved in the pathogenesis of osteoporosis, the signaling pathways associated with osteoporosis and trends in using stem cells as cell-based therapy for osteoporosis is summarized.

Pathogenesis

Imbalance of bone homeostasis

Bone formation generally comprises three basic steps: synthesis of extracellular protein matrix (osteoid) by osteoblasts; matrix mineralization by coating the protein matrix with a layer of mineral, and predominantly calcium phosphate in the form of crystals of hydroxyapatite; and bone remodeling, which is a process that occurs throughout human life. Bone remodeling is essential to maintain the integrity of the skeleton and serves as storage for mineral homeostasis [ 11 ]. Via an interactive process called coupling, this process is balanced by the functions of bone-resorbing osteoclasts and bone-forming osteoblasts in early adulthood. When the bone loses its mineral content and density and develops osteopenia, this culminates in osteoporosis, which is associated with a risk of bone fractures [ 11 , 12 ].

Osteoporosis is normally related to increasing age, consistent with the fact that most of the older population is affected by this condition. It has been shown that genetics could be another explanation for the pathogenesis of osteoporosis. The results of laboratory studies have indicated that osteoporosis is caused by an imbalance of the coupling interactive process, with increased bone resorption relative to bone formation. In this regard, the imbalance is a consequence of changes at the cellular level, by which osteoclast development is enhanced but osteoblast differentiation is insufficient because of impaired activity and enhanced apoptosis [ 13 , 14 ].

Underlying transcriptional regulation and genetics

Although MSCs have the ability to undergo multipotent differentiation, cell fate determination and differentiation toward either osteoblasts or adipocytes are well regulated by lineage-specific transcription factors such as runt-related transcription factor 2 (Runx2) and osterix (Osx) for osteoblasts and peroxisome proliferator-activated receptor gamma (PPARγ) for adipocytes, suggesting an inverse correlation between osteogenesis and adipogenesis [ 15 – 19 ]. During these processes, intrinsic (genetic) and/or environmental (local and/or systemic) conditions interplay to specify cell fate toward one of the possible lineages. Several lines of evidence have demonstrated that osteoporotic MSCs have defects in intrinsic signals that cause functional alterations, leading to poor osteogenic differentiation capacity and favoring increased adipogenesis [ 13 , 20 ]. A recent study of microarray analyses demonstrated that MSCs from elderly patients with primary osteoporosis have a distinct transcriptome compared with control MSCs and elderly donor non-osteoporotic MSCs, as shown by enhanced mRNA expression of osteoporosis-associated genes ( RUNX2, lipoprotein receptor-related protein 5; LRP5, collagen type 1 alpha1; COL1A1 ), genes involved in osteoclastogenesis ( CSF1, PTH1R ), and genes coding for inhibitors of wingless-type MMTV integration site family (Wnt) and bone morphogenetic protein (BMP) signaling, indicating intrinsic deficiencies in self-renewal and differentiation potential in osteoporotic MSCs [ 21 ]. Interestingly, transcriptional alterations may reflect epigenetic changes as part of the process of age-related osteoporosis [ 21 ].

Nevertheless, the regulatory mechanisms underlying the pathogenesis of osteoporosis have been linked to genetics. Several approaches, including linkage analysis in families, animal studies, candidate gene association studies, and genome-wide association studies (GWAS), have been used to identify the genes responsible for osteoporosis [ 22 ]. Linkage analysis is the classical approach that is used to study BMD variation [ 23 , 24 ]. Linkage studies in animals such as mice, rats and primates provide another way to identify genes that regulate bone density and other phenotypes relevant to osteoporosis. The Alox15 gene has been found to regulate bone density in mice, and this finding was confirmed in Alox15 -knockout mice showing increased BMD [ 25 ]. Candidate gene association studies have been widely used in the field of osteoporosis, analyzing polymorphic variants in candidate genes and relating them to the carriage of a specific allele or haplotype. Candidate genes such as sclerostin ( SOST ), COL1A1 , ESR1 , LRP5 , TGF-β1 and VDR have been extensively investigated on a large scale [ 26 – 40 ]. Due to advances in genotyping technologies, GWAS have been applied to study osteoporosis, and large numbers of single-nucleotide polymorphisms (SNPs) have been identified. A GWAS by Richards et al. reported the identification of SNPs that are significantly associated with decreased BMD and increased risks of osteoporotic fractures and osteoporosis when they are located near the TNFRSF11B (osteoprotegerin or OPG) and LRP5 genes [ 41 ]. Another study, by Styrkarsdottir et al., used an extended GWAS to identify four new genome-wide significant loci; this loci were near the SOST gene at 17q21, the MARK3 gene at 14q32, the SP7 gene at 12q13 and the TNFRSF11A (receptor activator of nuclear factor kB or RANK) gene at 18q21 and were associated with the heritability of BMD [ 42 ]. However, genetic studies of osteoporosis-susceptibility genes need to be further explored.

Signaling pathways associated with osteoporosis

Over several decades, signaling pathways in bone homeostasis have been extensively studied. Dysregulation of these signaling pathways is associated with bone diseases, including osteoporosis. Major signaling pathways that govern the bone regenerative process are OPG/RANK/RANK ligand (RANKL), Wnt, and BMP signaling.

Bone homeostasis is maintained by the balanced function of osteoblasts and osteoclasts. The key regulators involved in this balancing process, equilibrating between bone formation and bone resorption, have been extensively explored. The OPG/RANK/RANKL system is one of the most important signaling pathways in bone metabolism (Fig. 1 ). Dysregulation of the OPG/RANK/RANKL system has been reported in osteoporosis. OPG, recently designated as TNFRSF11B and serving as a member of the tumor necrosis factor (TNF) receptor family, was first identified as a crucial component that is secreted by osteoblasts; bone marrow stromal cells [ 43 ]; and other cells, such as regulatory T (T reg) cells [ 44 ]. OPG protects the skeleton from excessive bone resorption by acting as a soluble decoy receptor that can bind to RANKL [ 45 ]. The binding of OPG and RANKL subsequently prevents RANKL from binding to its receptor, RANK [ 43 ]. The overexpression of the gene encoding OPG results in the development of high bone mass and reduced osteoclast numbers and activity [ 46 ]. OPG-deficient mice demonstrate osteoporosis, with an excessive number of osteoclasts [ 47 , 48 ]. RANKL functions as an osteoclast-activating factor secreted by activated T cells and represents a potent molecule that binds to RANK, which is expressed on osteoclast precursors, known as preosteoclasts [ 49 ]. RANKL-RANK binding drives osteoclast differentiation and maturation. The activation of RANK through the binding of RANKL induces the activation of transcription factors such as c-fos, NFAT, and nuclear factor kappa B (NF-kB) in preosteoclasts and initiates several downstream signaling pathways, and especially the NF-kB pathway [ 50 , 51 ]. RANKL-deficient mice exhibit osteopetrotic bones, or thickened bones, due to a defect in osteoclast development [ 52 ]. Moreover, RANKL relies on the presence of macrophage colony-stimulating factor (M-CSF), which is a cofactor for RANKL/RANK-mediated osteoclastogenesis [ 53 ]. However, experimental data revealed that RANKL alone could stimulate bone resorption in mice lacking M-CSF [ 54 ]. In contrast, M-CSF alone is insufficient to activate osteoclasts [ 55 ]. Therefore, RANKL plays a crucial role in osteoclastogenesis, and this phenomenon is required for bone resorption. Under physiologic conditions, OPG/RANKL is in equilibrium and preserves bone homeostasis. The OPG/RANKL ratio is an important factor to use to determine bone mass and skeletal integrity [ 56 , 57 ]. Under osteoporotic conditions, RANKL is upregulated, which is associated with downregulation of OPG [ 58 ]. Moreover, several cytokines are elevated, and particularly TNF-α, IL-1, IL-4 and IL-6, in osteoporosis [ 59 ]. These proinflammatory cytokines modulate the RANKL/RANK ratio by stimulating and upregulating RANKL expression on T cells. Interestingly, this emerging role of the OPG/RANK/RANKL system not only is relevant to bone biology but also has been discovered beyond the immunological system. The cross-regulation between bone and immune cells is considered as a bone immunological niche [ 60 ]. Considering bone resorption, data in the literature have revealed that impairment of T cell subpopulations and their proinflammatory cytokine patterns are implicated in the pathogenesis of osteoporosis. At the bone tissue level, Th1 and Th2 cells play a role through their secreted cytokines, including RANKL, mediating osteoclast formation and activity, which are linked to bone resorption [ 61 ]. Furthermore, Th17 cells, a distinct lineage of proinflammatory T helper cells, were more recently identified as a potent T cell subpopulation that has a role in bone destruction [ 62 ]. Th17 cells have been found to increase in number in many bone diseases, and particularly osteoporosis [ 63 ]. Th17 cells produce IL-17, which functions in mediating osteoclast differentiation [ 63 , 64 ]. It has been shown that Th17 cells also produce RANKL, directly contributing to bone loss [ 62 ]. Additionally, the Th17 population in the bone marrow and peripheral blood is large in estrogen-deficient osteoporosis [ 65 ]. Collectively, Th1/Th2/Th17 cells and their cytokines might play a key role as potent pro-osteoclastogenic mediators underlying the pathogenesis of osteoporotic development. Fig. 1 Bone homeostasis regulation by OPG/RANK/RANKL system. RANKL which secreted by activated T cells functions as an osteoclast-activating factor by binding to its receptor, RANK, which is expressed on preosteoclasts. RANKL-RANK binding induces the activation of several transcription factors in preosteoclasts and initiates several downstream signaling pathways that drive osteoclast differentiation and maturation. OPG which secreted by osteoblasts, bone marrow stromal cells, and T reg cells acts as a soluble receptor that can bind to RANKL and subsequently prevents RANKL-RANK binding. Under physiologic conditions, OPG/RANKL is in equilibrium and preserves bone homeostasis. Under osteoporotic conditions, RANKL is upregulated, which is associated with downregulation of OPG. Several proinflammatory cytokines are secreted from T helper cells (Th1/Th2/Th17) stimulating and upregulating RANKL expression and mediating osteoclast formation and activity, which are linked to increased bone resorption

Wnts are secreted glycoproteins that, when bound to their cognate receptors, can stimulate intracellular signaling cascades that play important roles in cell developmental processes, including osteogenesis [ 66 , 67 ]. The binding of Wnt ligand to Frizzled receptor and the LRP6 coreceptors to form a complex stimulates the canonical Wnt/β-catenin pathway, whereas binding to the ROR2/RYK coreceptors stimulates non-canonical Wnt signaling [ 68 ]. In fact, signaling induced by Wnt/β-catenin is well established and generally plays a role in osteoblastogenesis by promoting the commitment and differentiation of MSCs toward the osteoblast lineage, which in turn suppresses adipogenesis through the inhibition of PPARγ-induced genes [ 66 , 69 ]. Wnt/β-catenin signaling plays a role in osteoblast maturation and indirectly reduces osteoclastogenesis by stimulating the secretion of OPG, a natural inhibitor of RANKL [ 70 , 71 ]. Considering the components of Wnt signaling, humans and mice with altered expression of LRP5 and Wnt10b have alterations in bone mass [ 72 , 73 ]. Loss-of-function LRP5 mutation causes abnormality in bone formation [ 72 ]. A genetic study found that WNT10B polymorphisms have an impact on low bone mass and osteoporosis risk [ 74 ]. As previously stated, Wnt10b seems to be the most positive modulator of bone regeneration and homeostasis. Supporting these findings, a decreased number and decreased function of osteoblasts have been found in Wnt10b -/- knockout mice, coupled with a 30 % reduction in bone volume and BMD [ 75 , 76 ]. Stevens et al. have found that heterozygous Wnt10b +/- mice showed a significant reduction in trabecular bone at 6 months of age, and both the number of bone marrow-derived MSCs and osteoblast differentiation were affected [ 76 ]. In another study, signaling through Wnt2, Wnt3 or Wnt3a induced proliferation and maintained the self-renewal of MSCs, whereas Wnt5a, Wnt5b or Wnt11 supported osteogenesis [ 77 , 78 ]. β -catenin deficiency arrests osteoblast development at an early stage in mesenchymal osteoblastic precursors and impairs the maturation and mineralization of committed osteoblasts [ 67 , 79 ]. Rodríguez et al. reported that osteoporotic MSCs had a diminished proliferation rate as well as decreased mRNA expression of Wnt signaling and the downstream components GSK-3β, LRP6 and OSX [ 28 , 80 ]. In addition, dickkopf-1 (DKK-1) and SOST are endogenous inhibitors of the canonical Wnt/β-catenin pathway that is specific to bone [ 70 , 81 ]. Genes coding for these inhibitors show enhanced expression in osteoporotic MSCs in humans [ 35 ]. Clinically, the serum DKK-1 level has been found to be significantly higher in patients with low BMD and postmenopausal osteoporosis [ 82 ]. Several findings have revealed crosstalk between Wnt signaling and other signaling factors, such as BMPs. In particular, BMP-2 has a synergistic effect with Wnt ligands and β-catenin, inducing bone formation through Wnt/β-catenin signaling and downstream T cell factor/lymphoid enhancer factor (TCF/LEF) transcriptional activity [ 83 , 84 ].

In addition to Wnt signaling, the BMPs, belonging to the transforming growth factor beta (TGF-β) superfamily, are responsible for numerous cell regulatory processes, including osteogenic differentiation and regulation of bone formation [ 85 ]. Upon binding of BMP ligand, signal transduction is initiated through the interaction between two serine-threonine kinase cell surface receptors (BMP receptors (BMPRs)). In particular, BMPR-IA and BMPR-IB are involved in MSC differentiation [ 86 ]. BMP-2, BMP-4, BMP-7, BMP-9, and BMP-13 are commonly studied in the context of MSC differentiation-related osteoblastogenesis and bone formation [ 87 , 88 ]. Notably, BMP-2 promotes Runx2 expression in mesenchymal osteoprogenitors and also promotes Osx and distal-less homeobox 5 (Dlx5) expression in osteoblasts [ 89 – 93 ]. BMP-3 is an exception because it inhibits osteogenesis [ 94 ]. BMPs function as both autocrine and paracrine factors, and their synthesis is induced by BMPs themselves via local feedback mechanisms. Evidence has shown that MSCs from osteoporosis patients are impaired in function and this alteration is associated with BMP signaling [ 95 , 96 ]. However, BMP antagonists have been described, including noggin (NOG) and gremlin (GREM). Overexpression of NOG, as shown in transgenic mouse studies, results in decreased BMD because of increased inhibition of bone formation [ 97 , 98 ]. SNPs in the NOG gene are associated with osteoporosis-related phenotypes in humans [ 99 ]. GREM is detectable in the skeleton, and its overexpression causes osteopenia and fractures [ 100 ]. Genetic variants of GREM2 are associated with BMD, and GREM2 is considered a susceptibility gene for osteoporosis [ 101 ].

Osteoporosis treatments

Current options for the treatment of osteoporosis are predominantly drug-based agents that either inhibit bone resorption or directly stimulate bone generation to increase bone mass. Non-pharmacological treatments via calcium and vitamin D consumption have been given to patients who have a high risk of osteoporosis related to insufficient calcium and vitamin D intake and postmenopause [ 102 , 103 ]. Pharmacological treatments are given to patients who are diagnosed with osteoporosis who have already had a fracture or who have a high risk of osteoporotic fracture or re-fracture. Bisphosphonates, which are synthetic compounds that decrease bone resorption by promoting osteoclast apoptosis [ 104 , 105 ], are the most common medications prescribed as first-line drugs for osteoporosis treatment. Several bisphosphonates have been approved as drugs for the treatment of osteoporosis, including alendronate [ 106 ], ibandronate [ 107 ], risedronate [ 108 ], and zoledronate [ 109 ]. However, serious side effects, such as osteonecrosis of the jaw and atypical femoral fractures, have been described in patients under long-term bisphosphonate treatment [ 110 , 111 ]. Although serious adverse events are rare for current antiresorptive compounds and do not represent a major concern, the development of drugs with higher efficacy in improvement of bone quality and prevention of fractures is still necessary. Other antiresorptive drugs that can serve as alternatives for osteoporosis treatment include denosumab, a RANKL inhibitor that blocks the main pathway involved in osteoclast formation and activation [ 112 ], and calcitonin, a naturally occurring peptide [ 113 ]. Hormone therapy, such as therapy with estrogen [ 114 ] and with selective estrogen receptor modulators (SERMs) acting as estrogen agonists, such as raloxifene [ 115 ], has been used in postmenopausal women to slow the bone breakdown process, maintain bone density, and reduce fracture risk. However, long-term side effects, and particularly the development of breast cancer, and risks of cardiovascular events and thromboembolism limit the use of estrogen and SERMs as treatment strategies for osteoporosis [ 116 , 117 ].

In contrast with antiresorptive drugs, anabolic drugs that can increase bone formation, rather than preventing bone loss, are of interest to rebuild bone, increase bone strength, and reduce the risk of fractures in osteoporosis patients. To date, approved anabolic drugs have been limited to parathyroid hormone (PTH) and its analog, teriparatide (recombinant human PTH(1–34)), which are considered as treatments for patients with severe osteoporosis. Nevertheless, it was reported that administering a high dose of teriparatide for a long period increased the incidence of osteosarcoma in an animal study [ 118 ]. Although evidence of osteosarcoma has not been reported in patients taking teriparatide, treatment with teriparatide is not allowed beyond 2 years according to the FDA. One therapeutic drug, strontium ranelate, which is thought to have dual actions on bone metabolism, both increasing bone formation and decreasing bone resorption, represents as a potential agent for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral and hip fractures [ 119 ]. Considering the costs and disadvantages of prolonged treatment with drugs and hormones in osteoporosis patients, cell therapy may be a good alternative candidate therapeutic strategy to treat osteoporosis in the future.

Stem cell-based therapy for osteoporosis

Cell therapy has attracted considerable clinical attention for the treatment of various diseases for many decades. Stem cells are believed to be an ideal source of cells for cell replacement therapy for bone diseases due to their properties of self-renewal and plasticity, which can repair or regenerate damaged tissues. Candidate stem cell types include embryonic stem (ES) cells, induced pluripotent stem (iPS) cells and somatic stem cells such as MSCs. The use of ES and iPS cells is limited due to ethical issues and virus-based derivation methods [ 120 ]. It seems likely that the use of MSCs overcomes such limitations and is more practical in other disease models. In recent years, MSCs have become dramatically interesting for the treatment of osteoporosis. MSCs have the ability to self-renew and to grow into specific tissues, such as cartilage, bone, and adipose tissue. Human MSCs are defined by their phenotypic expression of CD105, CD73 and CD90; their absence of expression of hematopoietic markers such as CD45, CD34, and CD14; and their ability to differentiate into osteogenic, adipogenic and chondrogenic lineages under permissive conditions [ 121 ]. It has been reported that MSCs can avoid allogeneic rejection by being hypoimmunogenic, modulating the T cell phenotype, and creating an immunosuppressive locus [ 122 ]. Moreover, MSC-derived osteogenic cells show immunoprivileged and immunomodulatory properties similar to those of their parental MSCs [ 123 ]. With regard to the pathogenesis of osteoporosis, resulting in bone mass reduction, transplantation of MSCs might promote new bone formation and strengthen the bone, contributing to improvement of bone quality and prevention of fractures. After transplantation, MSCs contribute to bone formation by two possible mechanisms of action: (1) MSCs’ homing to a damaged site or pathologic area and then differentiating into bone-forming cells to repair the degenerated tissue and (2) MSCs’ acting in a paracrine manner by secreting certain growth factors that modify the environment and recruit resident cells to repair the degenerated tissue [ 124 , 125 ].

Sources of mesenchymal stem cells: advantages and disadvantages

Bone marrow-derived MSCs

Bone marrow is the most commonly used tissue source of adult MSCs. Bone marrow-derived MSCs (BM-MSCs) have been extensively studied in bone regeneration and repair due to their high efficiency in osteogenic differentiation. Studies in animal models have revealed that both allogeneic and autologous BM-MSC transplantation is applicable in the treatment of osteoporosis. Ichioka et al. demonstrated that normal allogeneic BM-MSCs could increase trabecular bone and attenuate the loss of BMD after being directly injected into the bone marrow cavity of an irradiated P6 substrain of senescence-accelerated mice (SAMP6), an osteoporotic mouse model that exhibits age-dependent inhibition of osteoblastogenesis and osteoclastogenesis along with enhanced adipogenesis [ 126 ]. A similar result was also observed in an ovariectomy (OVX)-induced rat model of osteoporosis after receipt of allogeneic BM-MSCs isolated from healthy rats [ 127 ]. Autologous BM-MSC transplantation was reported to improve bone formation and to strengthen osteoporotic bone in an OVX-induced rabbit model of osteoporosis [ 128 ] as well as in goats with long-term estrogen deficiency, mimicking the postmenopausal osteoporosis that occurs in humans [ 129 ]. However, use of autologous BM-MSCs for osteoporosis treatment in elderly patients is limited due to the age-related decline in the overall BM-MSC number [ 130 ]. Recently, use of autologous BM-MSCs for the treatment of osteoporosis has been performed in clinical trial study. Autologous BM-MSCs were collected 30 days before infusion, and the cells were cultured under GMP conditions to establish the dose range. In this study, the cells were subjected to the process of fucosylation before intravenous infusion into osteoporosis patients. However, this study is still in the process of recruiting participants and is thus not yet completed (ClinicalTrials.gov Identifier: NCT02566655 ).

Adipose tissue-derived MSCs

Adipose tissue provides an attractive source of MSCs that has become increasingly popular in many stem cell applications. Adipose tissue-derived MSCs (AD-MSCs) are isolated from white adipose tissues via a minimally invasive approach and can be expanded and differentiated into classical mesenchymal lineages involved in adipogenesis, osteogenesis, and chondrogenesis [ 131 , 132 ]. AD-MSCs are more easily isolated and more abundant and produce higher yields in terms of cell number compared with BM-MSCs [ 133 ]. However, the yield of AD-MSCs and their proliferative and differentiation capacities vary depending on the tissue harvesting site [ 134 ] and the age of the donor [ 135 ]. For application in cell therapy for osteoporosis, AD-MSCs were reported to function as an effective autologous cell-based approach for the treatment of osteoporosis. SAMP6 osteoporosis mice showed significant improvement in several trabecular bone parameters after a single intratibial transplantation of isogenic AD-MSCs [ 136 ]. A preclinical study of the in vivo function of human AD-MSCs by Cho et al. revealed that human AD-MSCs could prevent OVX-induced bone loss in nude mice over 8 weeks, even though there was no evidence of long-term engraftment of infused human AD-MSCs in the bone of recipient mice [ 137 ]. The effect of human AD-MSC therapy likely occurs in a paracrine manner by the secretion of various bone-related growth factors, e.g., hepatocyte growth factor, BMP-2, and RANKL, and extracellular matrix (ECM) proteins, e.g., fibronectin, which might promote osteogenic differentiation, bone remodeling and repair in the recipients [ 124 ]. Moreover, Xinhai et al. demonstrated that autologous AD-MSCs enhanced bone regeneration in OVX-induced rabbit models of osteoporosis due to not only their own osteogenic differentiation but also their promotion of osteogenesis and inhibition of adipogenesis by osteoporotic BM-MSCs through activation of BMP-2 and the BMPR-IB signaling pathway [ 125 ]. Recently, a clinical trial has studied the use of human AD-MSCs for the treatment of proximal humeral fractures in individuals over 50 years old, representing a model for fractures of osteoporotic bone. In this study, AD-MSCs were wrapped around hydroxyapatite microgranules embedded in a fibrin gel to allow cellularized composite graft augmentation. Clinical/radiological follow-up was performed after 6, 9 and 12 months, and functional assessment was performed after 6 weeks and 6 and 12 months using the Quick DASH score and the Constant score. Unfortunately, the study was terminated, and no results are available (ClinicalTrials.gov Identifier: NCT01532076 ).

Perinatal-derived MSCs

Although BM- and AD-MSCs are effective sources, the therapeutic potential of these adult MSCs can be affected by the donor’s lifestyle and age. Perinatal tissues are alternative sources of MSCs that have attracted growing interest in bone regenerative medicine [ 138 ]. Not only are these cells younger than adult MSCs, but perinatal-derived MSCs also have the major advantage of an easy and noninvasive harvesting procedure without any risk to the donor. A comparative study of MSCs isolated from different perinatal tissue sites, including the umbilical cord, umbilical cord blood (UCB), amnion, and chorion, revealed that these tissues exhibit similar characteristics to BM-MSCs, including similar phenotypic features, growth properties, differentiation capacities, secretory protein profiles, and low immunogenic properties [ 138 ]. However, these stem cell sources are still limited by their low capacity to differentiate compared with BM- and AD-MSCs, and they have not been clearly examined in preclinical studies.

Placenta-derived MSCs

The placenta is an easily accessible source of perinatal MSCs that provides a high yield of MSCs. Placenta-derived MSCs (PL-MSCs) express common markers of MSCs and exhibit adipogenic, osteogenic, and neurogenic differentiation capacities [ 139 ]. Sanvoranart et al. demonstrated that PL-MSCs responded to bortezomib, a chemotherapeutic agent that improves osteolytic lesions in multiple myeloma, via enhancement of osteogenic differentiation, similarly to BM-MSCs [ 140 ]. This finding suggests the potential therapeutic application of PL-MSCs in osteopenia and osteoporosis patients.

Umbilical cord-derived MSCs

The umbilical cord contains various cell types, including vessels, connective tissues, and Wharton’s jelly. After isolation, these heterogeneous cells are observed to possess differential vimentin and cytokeratin expression in culture, but not variable capacities to differentiate into chondrogenic, adipogenic, and osteogenic lineages [ 141 ]. In vivo bone formation by umbilical cord-derived MSCs (UC-MSCs) was demonstrated by Diao et al., who loaded human UC-MSCs into scaffolds, implanted the scaffolds into BALB/c nude mice subcutaneously and found that the human UC-MSCs could efficiently form bone after implantation for 12 weeks [ 142 ].

Wharton’s jelly-derived MSCs

Wharton’s jelly is the mucoid connective tissue that surrounds the umbilical cord vein and that functions in the protection of the vasculature from pressure. Fibroblast-like cells were first isolated from Wharton’s jelly by McElreavey et al. in 1991 [ 143 ]. These fibroblast-like cells were characterized as MSCs due to their expression of MSC phenotypic markers and their capacities to differentiate into osteogenic, adipogenic, and chondrogenic lineages [ 144 ]. A comparative study of human derived-MSCs demonstrated that Wharton’s jelly-derived MSCs (WJ-MSCs) exhibited the strongest inhibitory effects on T cell proliferation and the weakest expression of immune-related genes, such as genes encoding major histocompatibility complex (MHC) II and human leukocyte antigen (HLA), compared with BM-, AD-, and PL-MSCs [ 145 ]. These immunomodulatory and immunosuppressive properties of WJ-MSCs make them more applicable for clinical use as cell therapy. A study in canines by Kang et al. revealed that canine WJ-MSCs were capable of forming new bone in recipients with bone defects after orthotopic implantation with beta tricalcium phosphate (β-TCP) for 20 weeks. The capacity of WJ-MSCs to undergo osteogenic differentiation in vitro and new bone formation in vivo was similar to that of other MSCs isolated from canine bone marrow, adipose tissue, and UCB [ 146 ]. Hence, WJ-MSCs can potentially be used in clinical bone engineering for further treatment of bone defect diseases.

Trends in stem cell therapy for osteoporosis

The main hurdles for stem cell-based therapy for osteoporosis are long-term engraftment and the uncertainty of stem cell fate after transplantation. Certain reports have revealed that long-term engraftment of MSCs appears to be low and that the function of MSCs might be mediated through a paracrine mechanism, rather than through sustained engraftment in injured tissues [ 137 , 147 , 148 ]. Senescence of MSCs has been investigated as one of the key factors affecting the growth of MSCs in vitro, possibly hampering the cells’ long-term survival after transplantation [ 149 ]. Many ongoing studies are aiming to develop high-quality in vitro MSC cultures to increase the survival and engraftment rates. These developing methodologies include modification of MSCs by certain factors and improvement of in vitro MSC culture systems and differentiation procedures. The adjustment of culture conditions before transplantation, such as hypoxic preconditioning of MSC cultures in vitro, has been performed to increase the proliferation rate and to enhance the differentiation potential as well as to induce mobilization and homing of MSCs following transplantation [ 150 , 151 ]. Genetically modified MSCs have been developed to ensure their homing, differentiation capacity, survival, and long-term engraftment at the injury sites of recipients. Immortalization of MSCs by knockdown of p53, a cell cycle regulator, in combination with overexpression of human telomerase reverse transcriptase (hTERT), the catalytic component of telomerase that leads to telomere elongation, could promote proliferation and increase the lifespan of MSCs while retaining the cells’ differentiation properties [ 152 ]. A combination of cell and gene therapy by overexpression of certain growth factors in MSCs has been promoted as being advantageous for MSC-based therapy [ 153 , 154 ]. For example, the ectopic expression of basic fibroblast growth factor (bFGF) and platelet-derived growth factor B (PDGF-B) enhanced the in vitro proliferation and osteogenesis of BM-MSCs while inhibiting their adipogenesis [ 154 ]. MSCs are also an attractive cellular vehicle for the in vivo delivery of therapeutic genes, such as the genes encoding BMP-2 and RANK-Fc (a soluble inhibitor of RANKL), which could increase bone formation in osteoporosis animal models [ 155 , 156 ]. Upon transplantation in vivo, the expressed transgene exerted its effect on both the host mesenchymal tissue (paracrine effect) and the transplanted MSCs (autocrine effect), contributing to the induction of bone formation in the recipients. These strategies of MSC modification are advantageous for the treatment of osteoporosis, which is characterized by increased bone resorption, and the therapies aim to maintain bone density and reduce the risk of fractures. To achieve effective MSC-based therapy for osteoporosis, the poor bone marrow homing and engraftment of MSCs after their systemic transplantation have to be improved. One emerging approach to overcome these limitations involves the overexpression of molecules involved in the bone homing of transplanted MSCs. Ectopic expression of α4 integrin on MSCs greatly increased bone marrow homing after systemic injection through the tail vein in immunocompetent mice. α4 integrin forms a heterodimer with endogenous β1 integrin and functions as a cell adhesion molecule, interacting with ECM proteins such as fibronectin and vascular cell adhesion protein 1 (VCAM-1) and thereby mediates the bone marrow homing and engraftment of MSCs [ 157 ]. Another study demonstrated that genetic modification of MSCs with CXCR4, the receptor for stromal-derived factor 1 (SDF-1), which mediates the bone marrow homing and engraftment of hematopoietic stem cells (HSCs), could also increase the bone marrow homing of MSCs and restore bone formation in mice with glucocorticoid-induced osteoporosis [ 158 ]. The development of in vitro differentiation procedures is quite important for MSCs used as cell therapy, especially for the treatment of localized osteoporosis and healing fractures resulting from osteoporosis. Technology consisting of three-dimensional (3D) in vitro culture models using biomaterial scaffolds has been developed, with the aim of mimicking the in vivo microenvironment to induce efficient tissue formation in vitro [ 159 ]. The biomaterial scaffolds must be slowly biodegradable and can act as a biocompatible matrix to support cell growth. In a recent preclinical study, Müller et al. demonstrated the combination of osteoconductive biomaterials with genetically modified human BM-MSCs in a bone defect rat model. The BM-MSCs were transduced with BMP-2 and loaded into β-TCP scaffolds before implantation into recipient rats. The researchers showed that when combined with BMP-2-transduced BM-MSCs, the scaffolds provided better results than scaffolds with recombinant BMP-2-treated BM-MSCs did [ 160 ]. This combination may represent a promising strategy for healing large-area bone defects in osteoporosis.

Alternative approaches involving improvement of native BM-MSCs or the local biologic environment at defect sites are of interest and are under investigation. Using a biomaterial scaffold combined with gene delivery for BMP-7 and PDGF-B expression has been shown to enhance the recruitment of BM-MSCs to defect sites and to promote their differentiation into osteoblasts, resulting in increased new bone formation in segmental femoral defects in ovariectomized rats [ 161 ]. α5β1 integrin, which mediates osteoblast differentiation in adult human MSCs through ECM-integrin interaction, is considered to be a target for promoting the osteogenic differentiation of BM-MSCs. The use of agonists that target α5β1 integrin can promote MSC recruitment and differentiation into osteoblasts and can also increase the survival of mature osteoblasts, leading to increased bone formation and repair in vivo [ 162 ]. Small molecules and microRNAs (miRNAs) are topics of interest in this area and may be applicable for osteoporosis treatment. Many miRNAs have been found to regulate the osteogenic differentiation of MSCs by various mechanisms [ 163 ]. Several miRNAs, e.g., miR-27a, miR-346, and miR-1423p, have been demonstrated to directly target inhibitors of the Wnt/β-catenin pathway, such as glycogen synthase kinase 3 beta (GSK3-β), SFRP1, and APC [ 164 – 166 ], resulting in modulation of the Wnt/β-catenin pathway and promotion of osteogenic differentiation of MSCs. Certain miRNAs, e.g., miR-20a, promote osteogenic differentiation by downregulating genes involved in adipogenic lineages, such as the gene encoding PPARγ [ 167 ]. By contrast, certain miRNAs negatively regulate osteogenic differentiation by targeting osteogenic genes, e.g., RUNX2 , OSX , and SATB2. Inhibition strategy using an antagomir sequence against these miRNAs might attenuate the expression of the osteogenic genes and subsequently induce osteogenic differentiation [ 168 – 170 ]. The discovery of small molecules that target MSCs for fate determination by using high-throughput screening (HTS) techniques provides an advantage in drug development for osteoporosis treatment [ 171 ]. Small molecules may directly stimulate signaling pathways or target genes involved in osteogenic differentiation of MSCs [ 172 – 174 ]. For example, simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, could promote osteogenic differentiation by activating the BMP-2 pathway in an ovariectomized rat model, leading to increasing BMD and bone volume [ 173 , 175 ]. Given this finding together with their other advantages, i.e., their small size, high stability, non-immunogenicity, and, most of all, cell permeability, small molecules have undoubted potential for treating osteoporosis.

Conclusion

Osteoporosis is a systemic bone disorder defined by low BMD occurring due to an imbalance of osteoclastic and/or osteoblastic activities. The current therapeutics for osteoporosis are based on medicine for the prevention of further bone loss. The serious side effects caused by prolonged treatment have led to a need for an alternative approach for the life-long treatment of osteoporosis. Cell therapy appears to fulfill this demand, and MSCs provide a promising source of cells for clinical application in the treatment of osteoporosis. MSCs have been widely used for osteoporosis research as well as in other bone diseases due to not only their intrinsic ability to differentiate into osteoblasts but also their availability and ease of isolation, with high cell yields, from various tissues. Moreover, the immunoprivileged and immunosuppressive properties of MSCs make them more applicable in allogeneic cell replacement therapy. To date, over 400 clinical trials of MSC therapies have been registered with ClinicalTrials.gov ( http://www.clinicaltrials.gov/ ); these trials have involved many diseases and conditions, such as bone disorders (osteoarthritis, osteogenesis imperfecta, osteoporosis, and rheumatoid arthritis), diabetes mellitus, graft-versus-host disease, and spinal cord injury. However, many questions remain unanswered, and many features have to be validated, such as the long-term engraftment and senescence of MSCs and suitable sources of MSCs for transplantation. In conclusion, much more work is needed to clarify the clinical applications of MSCs; however, the evidence certainly indicates that MSCs will play an important role in cell therapy for osteoporosis in the near future.

Abbreviations

3D, three-dimensional; AD, adipose tissue-derived; Alox15, arachidonate 15-lipoxygenase; bFGF, basic fibroblast growth factor; BM, bone marrow-derived; BMD, bone mineral density; BMP, bone morphogenetic protein; BMPR, bone morphogenetic protein receptor; CD, cluster of differentiation; COL1A1, collagen type 1 alpha1; CSF1, colony-stimulating factor 1; CXCR4, chemokine (c-x-c motif) receptor type 4; DKK-1, dickkopf-1; Dlx5, distal-less homeobox 5; DXA, dual-energy x-ray absorptiometry; ES, embryonic stem; ESR1, estrogen receptor 1; GREM, gremlin; GSK3β, glycogen synthase kinase 3 beta; GWAS, genome-wide association studies; HLA, human leukocyte antigen; HSC, hematopoietic stem cell; iPS, induced pluripotent stem; LRP5, lipoprotein receptor-related protein 5; MARK3, microtubule affinity regulation kinase 3; MHC, major histocompatibility complex; MSC, mesenchymal stem cell; NOG, noggin; OPG, osteoprotegerin; OSX, osterix; OVX, ovariectomy; PDGF-B, platelet-derived growth factor B; PL, placenta-derived; PPARγ, peroxisome proliferator-activated receptor gamma; PTH1R, parathyroid hormone 1 receptor; RANKL, receptor activator of nuclear factor kappa B ligand; RUNX2, runt-related transcription factor 2; SDF-1, stromal-derived factor-1; SERM, selective estrogen receptor modulator; SNPs, single nucleotide polymorphisms; SOST, sclerostin; SP7, Sp7 transcription factor 7; TCF/LEF, T cell factor/lymphoid enhancer factor; TGF-β, transforming growth factor beta; TNFRSF, tumor necrosis factor receptor superfamily; UC, umbilical cord-derived; UCB, umbilical cord blood; VDR, vitamin D receptor; WHO, World Health Organization; WJ, Wharton’s jelly-derived; Wnt, wingless-type MMTV integration site family; β-TCP, beta tricalcium phosphate.

This project was supported by Mahidol University.

Authors’ contributions

JP and TS: conception and drafting of manuscript; KN, NN, and KS: drafting of manuscript. VP: approval of manuscript. AS: conception and final approval of manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

References

1. Kanis JA Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group Osteoporos Int 1994 4 368 381 10.1007/BF01622200 7696835

2. Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 1137 1141 10.1002/jbmr.5650090802 7976495

3. Johnell O Kanis JA An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporos Int 2006 17 1726 1733 10.1007/s00198-006-0172-4 16983459

4. Dhanwal DK Dennison EM Harvey NC Cooper C Epidemiology of hip fracture: Worldwide geographic variation Indian J Orthop 2011 45 15 22 10.4103/0019-5413.73656 21221218 PMC3004072

5. Burge R Dawson-Hughes B Solomon DH Wong JB King A Tosteson A Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025 J Bone Miner Res 2007 22 465 475 10.1359/jbmr.061113 17144789

6. David C Confavreux CB Mehsen N Paccou J Leboime A Legrand E Severity of osteoporosis: what is the impact of co-morbidities? Joint Bone Spine 2010 77 Suppl 2 S103 S106 10.1016/S1297-319X(10)70003-8 21211745

7. Bonnick SL, Harris ST, Kendler DL, McClung MR, Silverman SL. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17:25–54. 10.1097/gme.0b013e3181c617e6 20061894

8. Vestergaard P Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis Osteoporos Int 2007 18 427 444 10.1007/s00198-006-0253-4 17068657

9. Eriksen EF Treatment of osteopenia Rev Endocr Metab Disord 2012 13 209 223 10.1007/s11154-011-9187-z 21710179 PMC3411311

10. Dawson-Hughes B Tosteson AN Melton LJ 3rd Baim S Favus MJ Khosla S Lindsay RL Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA Osteoporos Int 2008 19 449 458 10.1007/s00198-008-0559-5 18292975

11. Manolagas SC Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis Endocr Rev 2000 21 115 137 10782361 10.1210/edrv.21.2.0395

12. Zebaze RM Ghasem-Zadeh A Bohte A Iuliano-Burns S Mirams M Price RI Mackie EJ Seeman E Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study Lancet 2010 375 1729 1736 10.1016/S0140-6736(10)60320-0 20472174

13. Marie PJ Kassem M Osteoblasts in osteoporosis: past, emerging, and future anabolic targets Eur J Endocrinol 2011 165 1 10 10.1530/EJE-11-0132 21543379

14. Pino AM Rosen CJ Rodriguez JP In osteoporosis, differentiation of mesenchymal stem cells (MSCs) improves bone marrow adipogenesis Biol Res 2012 45 279 287 10.4067/S0716-97602012000300009 23283437 PMC8262098

15. Marie PJ Transcription factors controlling osteoblastogenesis Arch Biochem Biophys 2008 473 98 105 10.1016/j.abb.2008.02.030 18331818

16. James AW Review of Signaling Pathways Governing MSC Osteogenic and Adipogenic Differentiation Scientifica (Cairo) 2013 2013 684736 24416618 10.1155/2013/684736 PMC3874981

17. Valenti MT Garbin U Pasini A Zanatta M Stranieri C Manfro S Zucal C Dalle Carbonare L Role of ox-PAPCs in the differentiation of mesenchymal stem cells (MSCs) and Runx2 and PPARgamma2 expression in MSCs-like of osteoporotic patients PLoS One 2011 6 e20363 10.1371/journal.pone.0020363 21674037 PMC3108593

18. Zhang X Yang M Lin L Chen P Ma KT Zhou CY Ao YF Runx2 overexpression enhances osteoblastic differentiation and mineralization in adipose--derived stem cells in vitro and in vivo Calcif Tissue Int 2006 79 169 178 10.1007/s00223-006-0083-6 16969589

19. Issemann I Green S Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 1990 347 645 650 10.1038/347645a0 2129546

20. Cao JJ Effects of obesity on bone metabolism J Orthop Surg Res 2011 6 30 10.1186/1749-799X-6-30 21676245 PMC3141563

21. Benisch P Schilling T Klein-Hitpass L Frey SP Seefried L Raaijmakers N Krug M Regensburger M Zeck S Schinke T Amling M Ebert R Jakob F The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitors PLoS One 2012 7 e45142 10.1371/journal.pone.0045142 23028809 PMC3454401

22. Ralston SH Genetics of osteoporosis Ann N Y Acad Sci 2010 1192 181 189 10.1111/j.1749-6632.2009.05317.x 20392235

23. Peacock M Koller DL Lai D Hui S Foroud T Econs MJ Sex-specific quantitative trait loci contribute to normal variation in bone structure at the proximal femur in men Bone 2005 37 467 473 10.1016/j.bone.2005.05.005 16046210 PMC1513190

24. Wilson SG Reed PW Andrew T Barber MJ Lindersson M Langdown M Thompson D Thompson E Bailey M Chiano M Kleyn PW Spector TD A genome-screen of a large twin cohort reveals linkage for quantitative ultrasound of the calcaneus to 2q33-37 and 4q12-21 J Bone Miner Res 2004 19 270 277 10.1359/JBMR.0301224 14969397

25. Klein RF Allard J Avnur Z Nikolcheva T Rotstein D Carlos AS Shea M Waters RV Belknap JK Peltz G Orwoll ES Regulation of bone mass in mice by the lipoxygenase gene Alox15 Science 2004 303 229 232 10.1126/science.1090985 14716014

26. Grant SF Reid DM Blake G Herd R Fogelman I Ralston SH Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene Nat Genet 1996 14 203 205 10.1038/ng1096-203 8841196

27. Mann V Ralston SH Meta-analysis of COL1A1 Sp1 polymorphism in relation to bone mineral density and osteoporotic fracture Bone 2003 32 711 717 10.1016/S8756-3282(03)00087-5 12810179

28. Ralston SH Uitterlinden AG Brandi ML Balcells S Langdahl BL Lips P Lorenc R Obermayer-Pietsch B Scollen S Bustamante M Husted LB Carey AH Diez-Perez A Dunning AM Falchetti A Karczmarewicz E Kruk M van Leeuwen JP van Meurs JB Mangion J McGuigan FE Mellibovsky L del Monte F Pols HA Reeve J Reid DM Renner W Rivadeneira F van Schoor NM Sherlock RE Ioannidis JP Investigators, G Large-scale evidence for the effect of the COLIA1 Sp1 polymorphism on osteoporosis outcomes: the GENOMOS study PLoS Med 2006 3 e90 10.1371/journal.pmed.0030090 16475872 PMC1370920

29. Mann V Hobson EE Li B Stewart TL Grant SF Robins SP Aspden RM Ralston SH A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality J Clin Invest 2001 107 899 907 10.1172/JCI10347 11285309 PMC199568

30. Stewart TL Roschger P Misof BM Mann V Fratzl P Klaushofer K Aspden R Ralston SH Association of COLIA1 Sp1 alleles with defective bone nodule formation in vitro and abnormal bone mineralization in vivo Calcif Tissue Int 2005 77 113 118 10.1007/s00223-004-0188-8 15895281

31. Sano M Inoue S Hosoi T Ouchi Y Emi M Shiraki M Orimo H Association of estrogen receptor dinucleotide repeat polymorphism with osteoporosis Biochem Biophys Res Commun 1995 217 378 383 10.1006/bbrc.1995.2787 8526937

32. Albagha OM Pettersson U Stewart A McGuigan FE MacDonald HM Reid DM Ralston SH Association of oestrogen receptor alpha gene polymorphisms with postmenopausal bone loss, bone mass, and quantitative ultrasound properties of bone J Med Genet 2005 42 240 246 10.1136/jmg.2004.023895 15744038 PMC1736016

33. Boyden LM Mao J Belsky J Mitzner L Farhi A Mitnick MA Wu D Insogna K Lifton RP High bone density due to a mutation in LDL-receptor-related protein 5 N Engl J Med 2002 346 1513 1521 10.1056/NEJMoa013444 12015390

34. van Meurs JB Rivadeneira F Jhamai M Hugens W Hofman A van Leeuwen JP Pols HA Uitterlinden AG Common genetic variation of the low-density lipoprotein receptor-related protein 5 and 6 genes determines fracture risk in elderly white men J Bone Miner Res 2006 21 141 150 10.1359/JBMR.050904 16355283

35. Balemans W Foernzler D Parsons C Ebeling M Thompson A Reid DM Lindpaintner K Ralston SH Van Hul W Lack of association between the SOST gene and bone mineral density in perimenopausal women: analysis of five polymorphisms Bone 2002 31 515 519 10.1016/S8756-3282(02)00844-X 12398949

36. Uitterlinden AG Arp PP Paeper BW Charmley P Proll S Rivadeneira F Fang Y van Meurs JB Britschgi TB Latham JA Schatzman RC Pols HA Brunkow ME Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites Am J Hum Genet 2004 75 1032 1045 10.1086/426458 15514891 PMC1182139

37. Langdahl BL Knudsen JY Jensen HK Gregersen N Eriksen EF A sequence variation: 713-8delC in the transforming growth factor-beta 1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women Bone 1997 20 289 294 10.1016/S8756-3282(96)00363-8 9071481

38. Yamada Y Miyauchi A Goto J Takagi Y Okuizumi H Kanematsu M Hase M Takai H Harada A Ikeda K Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women J Bone Miner Res 1998 13 1569 1576 10.1359/jbmr.1998.13.10.1569 9783545

39. Langdahl BL Uitterlinden AG Ralston SH Trikalinos TA Balcells S Brandi ML Scollen S Lips P Lorenc R Obermayer-Pietsch B Reid DM Armas JB Arp PP Bassiti A Bustamante M Husted LB Carey AH Perez Cano R Dobnig H Dunning AM Fahrleitner-Pammer A Falchetti A Karczmarewicz E Kruk M van Leeuwen JP Masi L van Meurs JB Mangion J McGuigan FE Mellibovsky L Mosekilde L Nogues X Pols HA Reeve J Renner W Rivadeneira F van Schoor NM Ioannidis JP investigators, A., investigators, D., investigators, E., investigators, E., investigators, F., investigators, L., investigators, E. and Study, G Large-scale analysis of association between polymorphisms in the transforming growth factor beta 1 gene (TGFB1) and osteoporosis: the GENOMOS study Bone 2008 42 969 981 10.1016/j.bone.2007.11.007 18284942

40. Morrison NA Qi JC Tokita A Kelly PJ Crofts L Nguyen TV Sambrook PN Eisman JA Prediction of bone density from vitamin D receptor alleles Nature 1994 367 284 287 10.1038/367284a0 8161378

41. Richards JB Rivadeneira F Inouye M Pastinen TM Soranzo N Wilson SG Andrew T Falchi M Gwilliam R Ahmadi KR Valdes AM Arp P Whittaker P Verlaan DJ Jhamai M Kumanduri V Moorhouse M van Meurs JB Hofman A Pols HA Hart D Zhai G Kato BS Mullin BH Zhang F Deloukas P Uitterlinden AG Spector TD Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study Lancet 2008 371 1505 1512 10.1016/S0140-6736(08)60599-1 18455228 PMC2679414

42. Styrkarsdottir U Halldorsson BV Gretarsdottir S Gudbjartsson DF Walters GB Ingvarsson T Jonsdottir T Saemundsdottir J Snorradottir S Center JR Nguyen TV Alexandersen P Gulcher JR Eisman JA Christiansen C Sigurdsson G Kong A Thorsteinsdottir U Stefansson K New sequence variants associated with bone mineral density Nat Genet 2009 41 15 17 10.1038/ng.284 19079262

43. Boyce BF Xing L The RANKL/RANK/OPG pathway Curr Osteoporos Rep 2007 5 98 104 10.1007/s11914-007-0024-y 17925190

44. Zaiss MM Sarter K Hess A Engelke K Bohm C Nimmerjahn F Voll R Schett G David JP Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation Arthritis Rheum 2010 62 2328 2338 10.1002/art.27535 20506516

45. Min H Morony S Sarosi I Dunstan CR Capparelli C Scully S Van G Kaufman S Kostenuik PJ Lacey DL Boyle WJ Simonet WS Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis J Exp Med 2000 192 463 474 10.1084/jem.192.4.463 10952716 PMC2193236

46. Simonet WS Lacey DL Dunstan CR Kelley M Chang MS Luthy R Nguyen HQ Wooden S Bennett L Boone T Shimamoto G DeRose M Elliott R Colombero A Tan HL Trail G Sullivan J Davy E Bucay N Renshaw-Gegg L Hughes TM Hill D Pattison W Campbell P Sander S Van G Tarpley J Derby P Lee R Boyle WJ Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 1997 89 309 319 10.1016/S0092-8674(00)80209-3 9108485

47. Mizuno A Amizuka N Irie K Murakami A Fujise N Kanno T Sato Y Nakagawa N Yasuda H Mochizuki S Gomibuchi T Yano K Shima N Washida N Tsuda E Morinaga T Higashio K Ozawa H Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin Biochem Biophys Res Commun 1998 247 610 615 10.1006/bbrc.1998.8697 9647741

48. Bucay N Sarosi I Dunstan CR Morony S Tarpley J Capparelli C Scully S Tan HL Xu W Lacey DL Boyle WJ Simonet WS osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes Dev 1998 12 1260 1268 10.1101/gad.12.9.1260 9573043 PMC316769

49. Kong YY Feige U Sarosi I Bolon B Tafuri A Morony S Capparelli C Li J Elliott R McCabe S Wong T Campagnuolo G Moran E Bogoch ER Van G Nguyen LT Ohashi PS Lacey DL Fish E Boyle WJ Penninger JM Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand Nature 1999 402 304 309 10.1038/46303 10580503

50. Takayanagi H Kim S Koga T Nishina H Isshiki M Yoshida H Saiura A Isobe M Yokochi T Inoue J Wagner EF Mak TW Kodama T Taniguchi T Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts Dev Cell 2002 3 889 901 10.1016/S1534-5807(02)00369-6 12479813

51. Asagiri M Sato K Usami T Ochi S Nishina H Yoshida H Morita I Wagner EF Mak TW Serfling E Takayanagi H Autoamplification of NFATc1 expression determines its essential role in bone homeostasis J Exp Med 2005 202 1261 1269 10.1084/jem.20051150 16275763 PMC2213228

52. Jones DH Kong YY Penninger JM Role of RANKL and RANK in bone loss and arthritis Ann Rheum Dis 2002 61 Suppl 2 ii32 ii39 10.1136/ard.61.suppl_2.ii32 12379618 PMC1766717

53. Lacey DL Timms E Tan HL Kelley MJ Dunstan CR Burgess T Elliott R Colombero A Elliott G Scully S Hsu H Sullivan J Hawkins N Davy E Capparelli C Eli A Qian YX Kaufman S Sarosi I Shalhoub V Senaldi G Guo J Delaney J Boyle WJ Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 1998 93 165 176 10.1016/S0092-8674(00)81569-X 9568710

54. Kearns AE Khosla S Kostenuik PJ Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease Endocr Rev 2008 29 155 192 10.1210/er.2007-0014 18057140 PMC2528846

55. Hodge JM Collier FM Pavlos NJ Kirkland MA Nicholson GC M-CSF potently augments RANKL-induced resorption activation in mature human osteoclasts PLoS One 2011 6 e21462 10.1371/journal.pone.0021462 21738673 PMC3126821

56. Hofbauer LC Schoppet M Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases JAMA 2004 292 490 495 10.1001/jama.292.4.490 15280347

57. Rogers A Eastell R Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment J Clin Endocrinol Metab 2005 90 6323 6331 10.1210/jc.2005-0794 16105967

58. Mainini G Incoronato M Urso L Scaffa C Serum osteoprotegerin correlates with age and bone mass in postmenopausal, but not in fertile age women Clin Exp Obstet Gynecol 2011 38 355 359 22268274

59. Rifas L Bone and cytokines: beyond IL-1, IL-6 and TNF-alpha Calcif Tissue Int 1999 64 1 7 10.1007/s002239900570 9868276

60. Pagliari D Ciro Tamburrelli F Zirio G Newton EE Cianci R The role of “bone immunological niche” for a new pathogenetic paradigm of osteoporosis Anal Cell Pathol (Amst) 2015 2015 434389 26491648 10.1155/2015/434389 PMC4605147

61. Yuan FL Li X Lu WG Zhao YQ Li CW Li JP Sun JM Xu RS Type 17 T-helper cells might be a promising therapeutic target for osteoporosis Mol Biol Rep 2012 39 771 774 10.1007/s11033-011-0797-z 21556758

62. Sato K Suematsu A Okamoto K Yamaguchi A Morishita Y Kadono Y Tanaka S Kodama T Akira S Iwakura Y Cua DJ Takayanagi H Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction J Exp Med 2006 203 2673 2682 10.1084/jem.20061775 17088434 PMC2118166

63. Tyagi AM Srivastava K Mansoori MN Trivedi R Chattopadhyay N Singh D Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis PLoS One 2012 7 e44552 10.1371/journal.pone.0044552 22970248 PMC3438183

64. Korn T Oukka M Kuchroo V Bettelli E Th17 cells: effector T cells with inflammatory properties Semin Immunol 2007 19 362 371 10.1016/j.smim.2007.10.007 18035554 PMC2839934

65. Zhao R Immune regulation of bone loss by Th17 cells in oestrogen-deficient osteoporosis Eur J Clin Invest 2013 43 1195 1202 24033116 10.1111/eci.12158

66. Manolagas SC Wnt signaling and osteoporosis Maturitas 2014 78 233 237 10.1016/j.maturitas.2014.04.013 24815296 PMC4065196

67. Day TF Guo X Garrett-Beal L Yang Y Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis Dev Cell 2005 8 739 750 10.1016/j.devcel.2005.03.016 15866164

68. Hoeppner LH Secreto FJ Westendorf JJ Wnt signaling as a therapeutic target for bone diseases Expert Opin Ther Targets 2009 13 485 496 10.1517/14728220902841961 19335070 PMC3023986

69. Kang S Bennett CN Gerin I Rapp LA Hankenson KD Macdougald OA Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma J Biol Chem 2007 282 14515 14524 10.1074/jbc.M700030200 17351296

70. Krishnan V Bryant HU Macdougald OA Regulation of bone mass by Wnt signaling J Clin Invest 2006 116 1202 1209 10.1172/JCI28551 16670761 PMC1451219

71. Glass DA 2nd Bialek P Ahn JD Starbuck M Patel MS Clevers H Taketo MM Long F McMahon AP Lang RA Karsenty G Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation Dev Cell 2005 8 751 764 10.1016/j.devcel.2005.02.017 15866165

72. Gong Y Slee RB Fukai N Rawadi G Roman-Roman S Reginato AM Wang H Cundy T Glorieux FH Lev D Zacharin M Oexle K Marcelino J Suwairi W Heeger S Sabatakos G Apte S Adkins WN Allgrove J Arslan-Kirchner M Batch JA Beighton P Black GC Boles RG Boon LM Borrone C Brunner HG Carle GF Dallapiccola B De Paepe A Floege B Halfhide ML Hall B Hennekam RC Hirose T Jans A Juppner H Kim CA Keppler-Noreuil K Kohlschuetter A LaCombe D Lambert M Lemyre E Letteboer T Peltonen L Ramesar RS Romanengo M Somer H Steichen-Gersdorf E Steinmann B Sullivan B Superti-Furga A Swoboda W van den Boogaard MJ Van Hul W Vikkula M Votruba M Zabel B Garcia T Baron R Olsen BR Warman ML Osteoporosis-Pseudoglioma Syndrome Collaborative, G LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development Cell 2001 107 513 523 10.1016/S0092-8674(01)00571-2 11719191

73. Bennett CN Ouyang H Ma YL Zeng Q Gerin I Sousa KM Lane TF Krishnan V Hankenson KD MacDougald OA Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation J Bone Miner Res 2007 22 1924 1932 10.1359/jbmr.070810 17708715

74. Perez-Castrillon JL Olmos JM Nan DN Castillo J Arozamena J Montero A Perez-Nunez MI Riancho JA Polymorphisms of the WNT10B gene, bone mineral density, and fractures in postmenopausal women Calcif Tissue Int 2009 85 113 118 10.1007/s00223-009-9256-4 19458884

75. Bennett CN Longo KA Wright WS Suva LJ Lane TF Hankenson KD MacDougald OA Regulation of osteoblastogenesis and bone mass by Wnt10b Proc Natl Acad Sci U S A 2005 102 3324 3329 10.1073/pnas.0408742102 15728361 PMC552924

76. Stevens JR Miranda-Carboni GA Singer MA Brugger SM Lyons KM Lane TF Wnt10b deficiency results in age-dependent loss of bone mass and progressive reduction of mesenchymal progenitor cells J Bone Miner Res 2010 25 2138 2147 10.1002/jbmr.118 20499361 PMC3153316

77. Boland GM Perkins G Hall DJ Tuan RS Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells J Cell Biochem 2004 93 1210 1230 10.1002/jcb.20284 15486964

78. Ling L Nurcombe V Cool SM Wnt signaling controls the fate of mesenchymal stem cells Gene 2009 433 1 7 10.1016/j.gene.2008.12.008 19135507

79. Chen J Long F beta-catenin promotes bone formation and suppresses bone resorption in postnatal growing mice J Bone Miner Res 2013 28 1160 1169 10.1002/jbmr.1834 23188722 PMC3631304

80. Rodriguez JP Garat S Gajardo H Pino AM Seitz G Abnormal osteogenesis in osteoporotic patients is reflected by altered mesenchymal stem cells dynamics J Cell Biochem 1999 75 414 423 10.1002/(SICI)1097-4644(19991201)75:3<414::AID-JCB7>3.0.CO;2-C 10536365

81. Cruciat CM Niehrs C Secreted and transmembrane wnt inhibitors and activators Cold Spring Harb Perspect Biol 2013 5 a015081 10.1101/cshperspect.a015081 23085770 PMC3578365

82. Ahmed SF Fouda N Abbas AA Serum dickkopf-1 level in postmenopausal females: correlation with bone mineral density and serum biochemical markers J Osteoporos 2013 2013 460210 10.1155/2013/460210 23878759 PMC3710636

83. Mbalaviele G Sheikh S Stains JP Salazar VS Cheng SL Chen D Civitelli R Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation J Cell Biochem 2005 94 403 418 10.1002/jcb.20253 15526274 PMC2647989

84. Zhang M Yan Y Lim YB Tang D Xie R Chen A Tai P Harris SE Xing L Qin YX Chen D BMP-2 modulates beta-catenin signaling through stimulation of Lrp5 expression and inhibition of beta-TrCP expression in osteoblasts J Cell Biochem 2009 108 896 905 10.1002/jcb.22319 19795382 PMC2837602

85. Cheng H Jiang W Phillips FM Haydon RC Peng Y Zhou L Luu HH An N Breyer B Vanichakarn P Szatkowski JP Park JY He TC Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs) J Bone Joint Surg Am 2003 85-A 1544 1552 12925636 10.2106/00004623-200308000-00017

86. Chen D Ji X Harris MA Feng JQ Karsenty G Celeste AJ Rosen V Mundy GR Harris SE Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages J Cell Biol 1998 142 295 305 10.1083/jcb.142.1.295 9660882 PMC2133031

87. Knight MN Hankenson KD Mesenchymal Stem Cells in Bone Regeneration Adv Wound Care (New Rochelle) 2013 2 306 316 10.1089/wound.2012.0420 24527352 PMC3842877

88. Chen G Deng C Li YP TGF-beta and BMP signaling in osteoblast differentiation and bone formation Int J Biol Sci 2012 8 272 288 10.7150/ijbs.2929 22298955 PMC3269610

89. Zhang C Transcriptional regulation of bone formation by the osteoblast-specific transcription factor Osx J Orthop Surg Res 2010 5 37 10.1186/1749-799X-5-37 20550694 PMC2898801

90. Lee MH Kwon TG Park HS Wozney JM Ryoo HM BMP-2-induced Osterix expression is mediated by Dlx5 but is independent of Runx2 Biochem Biophys Res Commun 2003 309 689 694 10.1016/j.bbrc.2003.08.058 12963046

91. Holleville N Mateos S Bontoux M Bollerot K Monsoro-Burq AH Dlx5 drives Runx2 expression and osteogenic differentiation in developing cranial suture mesenchyme Dev Biol 2007 304 860 874 10.1016/j.ydbio.2007.01.003 17335796

92. Jeong HM Jin YH Kim YJ Yum J Choi YH Yeo CY Lee KY Akt phosphorylates and regulates the function of Dlx5 Biochem Biophys Res Commun 2011 409 681 686 10.1016/j.bbrc.2011.05.064 21619873

93. Choi YH Jeong HM Jin YH Li H Yeo CY Lee KY Akt phosphorylates and regulates the osteogenic activity of Osterix Biochem Biophys Res Commun 2011 411 637 641 10.1016/j.bbrc.2011.07.009 21777568

94. Daluiski A Engstrand T Bahamonde ME Gamer LW Agius E Stevenson SL Cox K Rosen V Lyons KM Bone morphogenetic protein-3 is a negative regulator of bone density Nat Genet 2001 27 84 88 11138004 10.1038/83810

95. Prall WC Haasters F Heggebo J Polzer H Schwarz C Gassner C Grote S Anz D Jager M Mutschler W Schieker M Mesenchymal stem cells from osteoporotic patients feature impaired signal transduction but sustained osteoinduction in response to BMP-2 stimulation Biochem Biophys Res Commun 2013 440 617 622 10.1016/j.bbrc.2013.09.114 24099772

96. Haasters F Docheva D Gassner C Popov C Bocker W Mutschler W Schieker M Prall WC Mesenchymal stem cells from osteoporotic patients reveal reduced migration and invasion upon stimulation with BMP-2 or BMP-7 Biochem Biophys Res Commun 2014 452 118 123 10.1016/j.bbrc.2014.08.055 25152406

97. Wu XB Li Y Schneider A Yu W Rajendren G Iqbal J Yamamoto M Alam M Brunet LJ Blair HC Zaidi M Abe E Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in noggin-overexpressing mice J Clin Invest 2003 112 924 934 10.1172/JCI15543 12975477 PMC193662

98. Devlin RD Du Z Pereira RC Kimble RB Economides AN Jorgetti V Canalis E Skeletal overexpression of noggin results in osteopenia and reduced bone formation Endocrinology 2003 144 1972 1978 10.1210/en.2002-220918 12697704

99. Moffett SP Dillon KA Yerges LM Goodrich LJ Nestlerode C Bunker CH Wheeler VW Patrick AL Zmuda JM Identification and association analysis of single nucleotide polymorphisms in the human noggin (NOG) gene and osteoporosis phenotypes Bone 2009 44 999 1002 10.1016/j.bone.2008.12.024 19167531

100. Gazzerro E Pereira RC Jorgetti V Olson S Economides AN Canalis E Skeletal overexpression of gremlin impairs bone formation and causes osteopenia Endocrinology 2005 146 655 665 10.1210/en.2004-0766 15539560

101. Cheung CL Lau KS Sham PC Tan KC Kung AW Genetic variants in GREM2 are associated with bone mineral density in a southern Chinese population J Clin Endocrinol Metab 2013 98 E1557 E1561 10.1210/jc.2013-1983 23902946

102. Dawson-Hughes B Harris SS Krall EA Dallal GE Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older N Engl J Med 1997 337 670 676 10.1056/NEJM199709043371003 9278463

103. Baccaro LF Conde DM Costa-Paiva L Pinto-Neto AM The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil Clin Interv Aging 2015 10 583 591 10.2147/CIA.S54614 25848234 PMC4374649

104. Van Beek ER Lowik CW Papapoulos SE Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors Bone 2002 30 64 70 10.1016/S8756-3282(01)00655-X 11792566

105. Rodan GA Reszka AA Bisphosphonate mechanism of action Curr Mol Med 2002 2 571 577 10.2174/1566524023362104 12243249

106. Papapoulos SE Quandt SA Liberman UA Hochberg MC Thompson DE Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women Osteoporos Int 2005 16 468 474 10.1007/s00198-004-1725-z 15448985

107. Inderjeeth CA Glendenning P Ratnagobal S Inderjeeth DC Ondhia C Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis Int J Womens Health 2015 7 7 17 25565901 10.2147/IJWH.S73944 PMC4274146

108. Harrington JT Ste-Marie LG Brandi ML Civitelli R Fardellone P Grauer A Barton I Boonen S Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis Calcif Tissue Int 2004 74 129 135 10.1007/s00223-003-0042-4 14648009

109. Black DM Delmas PD Eastell R Reid IR Boonen S Cauley JA Cosman F Lakatos P Leung PC Man Z Mautalen C Mesenbrink P Hu H Caminis J Tong K Rosario-Jansen T Krasnow J Hue TF Sellmeyer D Eriksen EF Cummings SR Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 2007 356 1809 1822 10.1056/NEJMoa067312 17476007

110. Yarom N Yahalom R Shoshani Y Hamed W Regev E Elad S Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome Osteoporos Int 2007 18 1363 1370 10.1007/s00198-007-0384-2 17598065

111. Abrahamsen B Eiken P Eastell R Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study J Bone Miner Res 2009 24 1095 1102 10.1359/jbmr.081247 19113931

112. Cummings SR San Martin J McClung MR Siris ES Eastell R Reid IR Delmas P Zoog HB Austin M Wang A Kutilek S Adami S Zanchetta J Libanati C Siddhanti S Christiansen C Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 2009 361 756 765 10.1056/NEJMoa0809493 19671655

113. Chesnut CH 3rd Silverman S Andriano K Genant H Gimona A Harris S Kiel D LeBoff M Maricic M Miller P Moniz C Peacock M Richardson P Watts N Baylink D A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study PROOF Study Group Am J Med 2000 109 267 276 10.1016/s0002-9343(00)00490-3 10996576

114. Rossouw JE Anderson GL Prentice RL LaCroix AZ Kooperberg C Stefanick ML Jackson RD Beresford SA Howard BV Johnson KC Kotchen JM Ockene J Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial Jama 2002 288 321 333 10.1001/jama.288.3.321 12117397

115. Ettinger B Black DM Mitlak BH Knickerbocker RK Nickelsen T Genant HK Christiansen C Delmas PD Zanchetta JR Stakkestad J Gluer CC Krueger K Cohen FJ Eckert S Ensrud KE Avioli LV Lips P Cummings SR Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 1999 282 637 645 10.1001/jama.282.7.637 10517716

116. Barrett-Connor E Mosca L Collins P Geiger MJ Grady D Kornitzer M McNabb MA Wenger NK Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 125 137 10.1056/NEJMoa062462 16837676

117. Anderson GL Limacher M Assaf AR Bassford T Beresford SA Black H Bonds D Brunner R Brzyski R Caan B Chlebowski R Curb D Gass M Hays J Heiss G Hendrix S Howard BV Hsia J Hubbell A Jackson R Johnson KC Judd H Kotchen JM Kuller L LaCroix AZ Lane D Langer RD Lasser N Lewis CE Manson J Margolis K Ockene J O'Sullivan MJ Phillips L Prentice RL Ritenbaugh C Robbins J Rossouw JE Sarto G Stefanick ML Van Horn L Wactawski-Wende J Wallace R Wassertheil-Smoller S Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 2004 291 1701 1712 10.1001/jama.291.14.1701 15082697

118. Vahle JL Sato M Long GG Young JK Francis PC Engelhardt JA Westmore MS Linda Y Nold JB Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety Toxicol Pathol 2002 30 312 321 10.1080/01926230252929882 12051548

119. Marie PJ Felsenberg D Brandi ML How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis Osteoporos Int 2011 22 1659 1667 10.1007/s00198-010-1369-0 20812008

120. Takahashi K Tanabe K Ohnuki M Narita M Ichisaka T Tomoda K Yamanaka S Induction of pluripotent stem cells from adult human fibroblasts by defined factors Cell 2007 131 861 872 10.1016/j.cell.2007.11.019 18035408

121. Dominici M Le Blanc K Mueller I Slaper-Cortenbach I Marini F Krause D Deans R Keating A Prockop D Horwitz E Minimal criteria for defining multipotent mesenchymal stromal cells The International Society for Cellular Therapy position statement Cytotherapy 2006 8 315 317 16923606 10.1080/14653240600855905

122. Ryan JM Barry FP Murphy JM Mahon BP Mesenchymal stem cells avoid allogeneic rejection J Inflamm (Lond) 2005 2 8 10.1186/1476-9255-2-8 16045800 PMC1215510

123. Liu H Kemeny DM Heng BC Ouyang HW Melendez AJ Cao T The immunogenicity and immunomodulatory function of osteogenic cells differentiated from mesenchymal stem cells J Immunol 2006 176 2864 2871 10.4049/jimmunol.176.5.2864 16493043

124. Lee K Kim H Kim JM Kim JR Kim KJ Kim YJ Park SI Jeong JH Moon YM Lim HS Bae DW Kwon J Ko CY Kim HS Shin HI Jeong D Systemic transplantation of human adipose-derived stem cells stimulates bone repair by promoting osteoblast and osteoclast function J Cell Mol Med 2011 15 2082 2094 10.1111/j.1582-4934.2010.01230.x 21159123 PMC4394219

125. Ye X Zhang P Xue S Xu Y Tan J Liu G Adipose-derived stem cells alleviate osteoporosis by enhancing osteogenesis and inhibiting adipogenesis in a rabbit model Cytotherapy 2014 16 1643 1655 10.1016/j.jcyt.2014.07.009 25231892

126. Ichioka N Inaba M Kushida T Esumi T Takahara K Inaba K Ogawa R Iida H Ikehara S Prevention of senile osteoporosis in SAMP6 mice by intrabone marrow injection of allogeneic bone marrow cells Stem Cells 2002 20 542 551 10.1634/stemcells.20-6-542 12456962

127. Ocarino Nde M Boeloni JN Jorgetti V Gomes DA Goes AM Serakides R Intra-bone marrow injection of mesenchymal stem cells improves the femur bone mass of osteoporotic female rats Connect Tissue Res 2010 51 426 433 10.3109/03008201003597049 20373890

128. Wang Z Goh J De Das S Ge Z Ouyang H Chong JS Low SL Lee EH Efficacy of bone marrow-derived stem cells in strengthening osteoporotic bone in a rabbit model Tissue Eng 2006 12 1753 1761 10.1089/ten.2006.12.1753 16889506

129. Cao L Liu G Gan Y Fan Q Yang F Zhang X Tang T Dai K The use of autologous enriched bone marrow MSCs to enhance osteoporotic bone defect repair in long-term estrogen deficient goats Biomaterials 2012 33 5076 5084 10.1016/j.biomaterials.2012.03.069 22504017

130. Stolzing A Jones E McGonagle D Scutt A Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies Mech Ageing Dev 2008 129 163 173 10.1016/j.mad.2007.12.002 18241911

131. Arana M Mazo M Aranda P Pelacho B Prosper F Adipose tissue-derived mesenchymal stem cells: isolation, expansion, and characterization Methods Mol Biol 2013 1036 47 61 10.1007/978-1-62703-511-8_4 23807785

132. Strem BM Hicok KC Zhu M Wulur I Alfonso Z Schreiber RE Fraser JK Hedrick MH Multipotential differentiation of adipose tissue-derived stem cells Keio J Med 2005 54 132 141 10.2302/kjm.54.132 16237275

133. Kern S Eichler H Stoeve J Kluter H Bieback K Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue Stem Cells 2006 24 1294 1301 10.1634/stemcells.2005-0342 16410387

134. Jurgens WJ Oedayrajsingh-Varma MJ Helder MN Zandiehdoulabi B Schouten TE Kuik DJ Ritt MJ van Milligen FJ Effect of tissue-harvesting site on yield of stem cells derived from adipose tissue: implications for cell-based therapies Cell Tissue Res 2008 332 415 426 10.1007/s00441-007-0555-7 18379826 PMC2386754

135. Choudhery MS Badowski M Muise A Pierce J Harris DT Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation J Transl Med 2014 12 8 10.1186/1479-5876-12-8 24397850 PMC3895760

136. Mirsaidi A Genelin K Vetsch JR Stanger S Theiss F Lindtner RA von Rechenberg B Blauth M Muller R Kuhn GA Hofmann Boss S Ebner HL Richards PJ Therapeutic potential of adipose-derived stromal cells in age-related osteoporosis Biomaterials 2014 35 7326 7335 10.1016/j.biomaterials.2014.05.016 24933514

137. Cho SW Sun HJ Yang JY Jung JY Choi HJ An JH Kim SW Kim SY Park KJ Shin CS Human adipose tissue-derived stromal cell therapy prevents bone loss in ovariectomized nude mouse Tissue Eng Part A 2012 18 1067 1078 10.1089/ten.tea.2011.0355 22220675

138. Bieback K Brinkmann I Mesenchymal stromal cells from human perinatal tissues: From biology to cell therapy World J Stem Cells 2010 2 81 92 10.4252/wjsc.v2.i4.81 21607124 PMC3097927

139. Yen BL Huang HI Chien CC Jui HY Ko BS Yao M Shun CT Yen ML Lee MC Chen YC Isolation of multipotent cells from human term placenta Stem Cells 2005 23 3 9 10.1634/stemcells.2004-0098 15625118

140. Sanvoranart T Supokawej A Kheolamai P U-Pratya Y Klincumhom N Manochantr S Wattanapanitch M Issaragrisil S Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues Biochem Biophys Res Commun 2014 447 580 585 10.1016/j.bbrc.2014.04.044 24747566

141. Karahuseyinoglu S Cinar O Kilic E Kara F Akay GG Demiralp DO Tukun A Uckan D Can A Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys Stem Cells 2007 25 319 331 10.1634/stemcells.2006-0286 17053211

142. Diao Y Ma Q Cui F Zhong Y Human umbilical cord mesenchymal stem cells: osteogenesis in vivo as seed cells for bone tissue engineering J Biomed Mater Res A 2009 91 123 131 10.1002/jbm.a.32186 18767055

143. McElreavey KD Irvine AI Ennis KT McLean WH Isolation, culture and characterisation of fibroblast-like cells derived from the Wharton's jelly portion of human umbilical cord Biochem Soc Trans 1991 19 29s 10.1042/bst019029s 1709890

144. Wang HS Hung SC Peng ST Huang CC Wei HM Guo YJ Fu YS Lai MC Chen CC Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord Stem Cells 2004 22 1330 1337 10.1634/stemcells.2004-0013 15579650

145. Li X Bai J Ji X Li R Xuan Y Wang Y Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation Int J Mol Med 2014 34 695 704 24970492 10.3892/ijmm.2014.1821 PMC4121354

146. Kang BJ Ryu HH Park SS Koyama Y Kikuchi M Woo HM Kim WH Kweon OK Comparing the osteogenic potential of canine mesenchymal stem cells derived from adipose tissues, bone marrow, umbilical cord blood, and Wharton's jelly for treating bone defects J Vet Sci 2012 13 299 310 10.4142/jvs.2012.13.3.299 23000587 PMC3467406

147. von Bahr L Batsis I Moll G Hagg M Szakos A Sundberg B Uzunel M Ringden O Le Blanc K Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation Stem Cells 2012 30 1575 1578 10.1002/stem.1118 22553154

148. Seebach E Freischmidt H Holschbach J Fellenberg J Richter W Mesenchymal stroma cells trigger early attraction of M1 macrophages and endothelial cells into fibrin hydrogels, stimulating long bone healing without long-term engraftment Acta Biomater 2014 10 4730 4741 10.1016/j.actbio.2014.07.017 25058402

149. Galderisi U Helmbold H Squillaro T Alessio N Komm N Khadang B Cipollaro M Bohn W Giordano A In vitro senescence of rat mesenchymal stem cells is accompanied by downregulation of stemness-related and DNA damage repair genes Stem Cells Dev 2009 18 1033 1042 10.1089/scd.2008.0324 19099372

150. Tsai CC Yew TL Yang DC Huang WH Hung SC Benefits of hypoxic culture on bone marrow multipotent stromal cells Am J Blood Res 2012 2 148 159 23119226 PMC3484415

151. Xu L Sun X Cao K Wu Y Zou D Liu Y Zhang X Zhang X Wang G Huang Q Jiang X Hypoxia induces osteogenesis in rabbit adipose-derived stem cells overexpressing bone morphogenic protein-2 Oral Dis 2014 20 430 439 10.1111/odi.12148 23865899

152. Liu TM Ng WM Tan HS Vinitha D Yang Z Fan JB Zou Y Hui JH Lee EH Lim B Molecular basis of immortalization of human mesenchymal stem cells by combination of p53 knockdown and human telomerase reverse transcriptase overexpression Stem Cells Dev 2013 22 268 278 10.1089/scd.2012.0222 22765508 PMC3545350

153. He X Dziak R Yuan X Mao K Genco R Swihart M Sarkar D Li C Wang C Lu L Andreadis S Yang S BMP2 genetically engineered MSCs and EPCs promote vascularized bone regeneration in rat critical-sized calvarial bone defects PLoS One 2013 8 e60473 10.1371/journal.pone.0060473 23565253 PMC3614944

154. Fierro FA Kalomoiris S Sondergaard CS Nolta JA Effects on proliferation and differentiation of multipotent bone marrow stromal cells engineered to express growth factors for combined cell and gene therapy Stem Cells 2011 29 1727 1737 10.1002/stem.720 21898687 PMC3784258

155. Kim D Cho SW Her SJ Yang JY Kim SW Kim SY Shin CS Retrovirus-mediated gene transfer of receptor activator of nuclear factor-kappaB-Fc prevents bone loss in ovariectomized mice Stem Cells 2006 24 1798 1805 10.1634/stemcells.2005-0480 16556708

156. Egermann M Baltzer AW Adamaszek S Evans C Robbins P Schneider E Lill CA Direct adenoviral transfer of bone morphogenetic protein-2 cDNA enhances fracture healing in osteoporotic sheep Hum Gene Ther 2006 17 507 517 10.1089/hum.2006.17.507 16716108

157. Kumar S Ponnazhagan S Bone homing of mesenchymal stem cells by ectopic alpha 4 integrin expression Faseb j 2007 21 3917 3927 10.1096/fj.07-8275com 17622670

158. Lien CY Chih-Yuan Ho K Lee OK Blunn GW Su Y Restoration of bone mass and strength in glucocorticoid-treated mice by systemic transplantation of CXCR4 and cbfa-1 co-expressing mesenchymal stem cells J Bone Miner Res 2009 24 837 848 10.1359/jbmr.081257 19113920

159. Sterling JA Guelcher SA Biomaterial scaffolds for treating osteoporotic bone Curr Osteoporos Rep 2014 12 48 54 10.1007/s11914-014-0187-2 24458428 PMC4048367

160. Muller CW, Hildebrandt K, Gerich T, Krettek C, van Griensven M, Balmayor ER. BMP-2-transduced human bone marrow stem cells enhance neo-bone formation in a rat critical-sized femur defect. J Tissue Eng Regen Med. 2015; doi:10.1002/term.2015. 10.1002/term.2015 25783748

161. Zhang Y Cheng N Miron R Shi B Cheng X Delivery of PDGF-B and BMP-7 by mesoporous bioglass/silk fibrin scaffolds for the repair of osteoporotic defects Biomaterials 2012 33 6698 6708 10.1016/j.biomaterials.2012.06.021 22763224 PMC5995476

162. Marie PJ Targeting integrins to promote bone formation and repair Nat Rev Endocrinol 2013 9 288 295 10.1038/nrendo.2013.4 23358353

163. van Wijnen AJ van de Peppel J van Leeuwen JP Lian JB Stein GS Westendorf JJ Oursler MJ Im HJ Taipaleenmaki H Hesse E Riester S Kakar S MicroRNA functions in osteogenesis and dysfunctions in osteoporosis Curr Osteoporos Rep 2013 11 72 82 10.1007/s11914-013-0143-6 23605904 PMC3678273

164. Guo D Li Q Lv Q Wei Q Cao S Gu J MiR-27a targets sFRP1 in hFOB cells to regulate proliferation, apoptosis and differentiation PLoS One 2014 9 e91354 10.1371/journal.pone.0091354 24625818 PMC3953332

165. Wang Q Cai J Cai XH Chen L miR-346 regulates osteogenic differentiation of human bone marrow-derived mesenchymal stem cells by targeting the Wnt/beta-catenin pathway PLoS One 2013 8 e72266 10.1371/journal.pone.0072266 24023731 PMC3762871

166. Hu W Ye Y Zhang W Wang J Chen A Guo F miR1423p promotes osteoblast differentiation by modulating Wnt signaling Mol Med Rep 2013 7 689 693 23229013 10.3892/mmr.2012.1207

167. Zhang JF Fu WM He ML Xie WD Lv Q Wan G Li G Wang H Lu G Hu X Jiang S Li JN Lin MC Zhang YO Kung HF MiRNA-20a promotes osteogenic differentiation of human mesenchymal stem cells by co-regulating BMP signaling RNA Biol 2011 8 829 838 10.4161/rna.8.5.16043 21743293

168. Huang J Zhao L Xing L Chen D MicroRNA-204 regulates Runx2 protein expression and mesenchymal progenitor cell differentiation Stem Cells 2010 28 357 364 20039258 10.1002/stem.288 PMC2837600

169. Deng Y Wu S Zhou H Bi X Wang Y Hu Y Gu P Fan X Effects of a miR-31, Runx2, and Satb2 regulatory loop on the osteogenic differentiation of bone mesenchymal stem cells Stem Cells Dev 2013 22 2278 2286 10.1089/scd.2012.0686 23517179

170. Zhang JF Fu WM He ML Wang H Wang WM Yu SC Bian XW Zhou J Lin MC Lu G Poon WS Kung HF MiR-637 maintains the balance between adipocytes and osteoblasts by directly targeting Osterix Mol Biol Cell 2011 22 3955 3961 10.1091/mbc.E11-04-0356 21880893 PMC3204058

171. Nawa K Ikeno H Matsuhashi N Ogasawara T Otsuka E Discovering small molecules that inhibit adipogenesis and promote osteoblastogenesis: unique screening and Oncostatin M-like activity Differentiation 2013 86 65 74 10.1016/j.diff.2013.07.005 23995451

172. Zhang JF Li G Chan CY Meng CL Lin MC Chen YC He ML Leung PC Kung HF Flavonoids of Herba Epimedii regulate osteogenesis of human mesenchymal stem cells through BMP and Wnt/beta-catenin signaling pathway Mol Cell Endocrinol 2010 314 70 74 10.1016/j.mce.2009.08.012 19703516

173. Ho ML Chen YH Liao HJ Chen CH Hung SH Lee MJ Fu YC Wang YH Wang GJ Chang JK Simvastatin increases osteoblasts and osteogenic proteins in ovariectomized rats Eur J Clin Invest 2009 39 296 303 10.1111/j.1365-2362.2009.02092.x 19292885

174. Darcy A Meltzer M Miller J Lee S Chappell S Ver Donck K Montano M A novel library screen identifies immunosuppressors that promote osteoblast differentiation Bone 2012 50 1294 1303 10.1016/j.bone.2012.03.001 22421346 PMC3352976

175. Chen PY Sun JS Tsuang YH Chen MH Weng PW Lin FH Simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 signaling pathway Nutr Res 2010 30 191 199 10.1016/j.nutres.2010.03.004 20417880